$1.84
▲ +0.5% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Overview
52-week range
$1.93
$4.94
0% of range
Avg surprise (last 3)
+1,612%
Avg reaction (last 2)
+1.6%
50% positive
Latest IV / EM
421%
EM ±24.9% · $2 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.16 | $-0.18 | +11.1% | -116.3% | -3.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.15 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.19 | $-0.25 | +24.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $0.98 | $0.02 | +4,800% | — | +6.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.28 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.36 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.35 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.45 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.52 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.18 | -$0.19 | +5.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-11M | — | $-11M | $-13M | $55M | — | $-18M | $-22M |
| Net income | $-9M | — | $-8M | $-11M | $57M | — | $-16M | $-20M |
| EPS (diluted) | $-0.16 | — | $-0.15 | $-0.19 | $0.98 | — | $-0.28 | $-0.36 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $30M | $21M | $31M | $30M | $98M | $36M | $23M | $33M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $123M | $132M | $139M | $147M | $156M | $101M | $116M | $127M |
| Total assets | $133M | $143M | $158M | $166M | $176M | $123M | $138M | $150M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $29M | $31M | $32M | $34M | $35M | $39M | $40M | $39M |
| Total equity | $104M | $112M | $126M | $133M | $142M | $83M | $97M | $111M |